DiscoverMPR Weekly DoseMPR Weekly Dose Podcast #259 — ACIP Hep B Recommendation; Retatrutide Shows Promise; Omisirge Approved; Counterfeit Ozempic Seized; Gene Tx Approved for Wiskott-Aldrich Syndrome
MPR Weekly Dose Podcast #259 — ACIP Hep B Recommendation; Retatrutide Shows Promise; Omisirge Approved; Counterfeit Ozempic Seized; Gene Tx Approved for Wiskott-Aldrich Syndrome

MPR Weekly Dose Podcast #259 — ACIP Hep B Recommendation; Retatrutide Shows Promise; Omisirge Approved; Counterfeit Ozempic Seized; Gene Tx Approved for Wiskott-Aldrich Syndrome

Update: 2025-12-12
Share

Description

ACIP votes to change hep B vaccination for infants; positive results for retatrutide; Omisirge approved; counterfeit Ozempic seized by FDA; gene therapy approved for Wiskott-Aldrich syndrome.

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

MPR Weekly Dose Podcast #259 — ACIP Hep B Recommendation; Retatrutide Shows Promise; Omisirge Approved; Counterfeit Ozempic Seized; Gene Tx Approved for Wiskott-Aldrich Syndrome

MPR Weekly Dose Podcast #259 — ACIP Hep B Recommendation; Retatrutide Shows Promise; Omisirge Approved; Counterfeit Ozempic Seized; Gene Tx Approved for Wiskott-Aldrich Syndrome